Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAVEN 3: Emicizumab Prophylaxis in Hemophilia A Without Inhibitors
NCT02847637Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2016
- Primary completion
- Sep 2017
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of emicizumab in hemophilia A, sponsored by Roche. Started Sep 2016; status: completed.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT02847637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02847637.